CHU Henri Mondor
Also known as: AP-HP Henri Mondor Créteil | Assistance Publique Hôpitaux de Paris - CHU Henri Mondor | Assistance Publique Hôpitaux de Paris- CHU Henri-Mondor | Centre Hospitalier Universitaire Henri Mondor | Centre Hospitalo-Universitaire Henri Mondor, Service d'Hematologie Clinique | CH Henri Mondor (Aurillac) | CHU d'HENRI MONDOR | CHU Henri-Mondor | CHU Henri Mondor, Créteil | CHU Henri Mondor de Creteil | Department of internal medicine, Henri-Mondor Hospital, Creteil, France. | Groupe Hospitalier Albert Chenevier Henri Mondor | Head of the department of rheumatology Hopital Henri Mondor, Creteil, France | Henri Mondor Hospital | Henri Mondor Hospital, Créteil, France | Henri Mondor Hospital (Paris) | Henri Mondor University Hospital | Hopital Henri Mondor | Hôpital Henri Mondor | Hôpital Henri Mondor, APHP CRETEIL | HOPITAL HENRI MONDOR - CRETEIL | Hopital Henri Mondor-France | Hôpitaux Universitaires Henri Mondor | HOSPITAL, HENRI MONDOR | Sebastien GALLIEN/Henri Mondor University Hospital- Infectiology Department | Service de médecine interne, Henri Mondor Hospital, APHP | THOMAS STEHL/ HENRI MONDOR HOSPITAL-Department of Nephrology | University Hospital, Henri Mondor/Albert Chenevier, Créteil
Highest phase reached
Phase 4
First clinical trial
Aug 1, 2002Last known activity
Jun 30, 2025
Timeline
1960s
- Jun 1, 1969
CHU Henri Mondor— Founded
Drugs by trial phase (76 distinct, 44 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (39 own, 0 via acquisition)
Phase 2 (20 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Other trials (7 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Albuminuria
- Anemia, Sickle Cell
- Blood Coagulation Disorders
- Breast Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Cystic Fibrosis
- Fibrosis
- Hemostatic Disorders
- Hepatitis C
- HIV Infections
- Hodgkin Disease
- Immunoblastic Lymphadenopathy
- Infarction
- Infections
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Liver Neoplasms
- Lung Diseases
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell
- Lymphopenia
- Monoclonal Gammopathy of Undetermined Significance
- Multiple Myeloma
- Multiple Sclerosis
- Mycoses
- Myelodysplastic Syndromes
- Myocardial Infarction
- Neoplasms, Plasma Cell
- Osteoarthritis
- Osteoarthritis, Hip
- Paraproteinemias
- Parkinson Disease
- Pleural Effusion
- Pleural Effusion, Malignant
- Polyneuropathies
- Preleukemia
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Sclerosis
- Shock
- Shock, Hemorrhagic
- Sinusitis
- Syndrome
- Thrombocytopenia
- Urticaria
Recent trials (50)
- NCT06892951CollaboratorPhase 1/Phase 2Jun 30, 2025
- NCT05519592Reponsible party - principal investigatorN/ASep 9, 2022
- NCT05519592Lead sponsorN/ASep 9, 2022
- NCT04993872CollaboratorPhase 4Oct 18, 2021
- NCT04993872CollaboratorPhase 4Oct 18, 2021
- NCT04844775CollaboratorPhase 1Jun 30, 2021
- NCT04842682Overall official - principal investigatorPhase 1Mar 29, 2021
- NCT04748796CollaboratorN/AFeb 1, 2021
- NCT04531046Overall official - principal investigatorPhase 2Jan 31, 2021
- NCT04703621CollaboratorPhase 2Jan 21, 2021
- NCT04120415CollaboratorPhase 2Nov 30, 2019
- NCT04113226CollaboratorPhase 2Oct 31, 2019
- NCT04113226Overall official - principal investigatorPhase 2Oct 31, 2019
- NCT03964792Study directorPhase 1/Phase 2Sep 1, 2019
- NCT03873727Overall official - principal investigatorPhase 2Apr 30, 2019
Details
- Founded
- Paris, FR Jun 1, 1969
- Last known activity
- Jun 30, 2025